發(fā)布時(shí)間：2018-06-03 05:26

  本文選題：恩替卡韋分散片 + 博路定�。� 參考：《廣東醫(yī)學(xué)》2016年08期

【摘要】：目的探討恩替卡韋分散片治療慢性乙型病毒性肝炎慢加急性肝衰竭的近期臨床療效。方法回顧性分析我院收治的98例慢性乙型病毒性肝炎慢加急性肝衰竭患者的臨床資料,分成觀察組和對(duì)照組,兩組均給予常規(guī)內(nèi)科綜合治療,56例應(yīng)用恩替卡韋分散片抗病毒治療者為觀察組,42例應(yīng)用恩替卡韋片抗病毒治療者為對(duì)照組。比較兩組患者治療后12周乙肝病毒DNA、肝功能、凝血酶原時(shí)間和治療12周后病死率的差異。結(jié)果兩組患者乙肝病毒DNA水平快速下降,治療第12周時(shí),觀察組中40例(71.43%)乙肝病毒DNA500 IU/m L,對(duì)照組中31例(73.81%)乙肝病毒DNA500 IU/m L,兩組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(醊2=0.068,P0.05)。12周時(shí),兩組患者的丙氨酸轉(zhuǎn)氨酶、天門(mén)氨酸轉(zhuǎn)氨酶、總膽紅素較治療前顯著下降,血清白蛋白明顯提高,PT明顯縮短,組間比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。至12周時(shí),觀察組病死率32.14%(18/56),對(duì)照組病死率30.95%(13/42),兩組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。兩組均無(wú)不良反應(yīng)發(fā)生。結(jié)論恩替卡韋分散片治療慢性乙型病毒性肝炎慢加急性肝衰竭時(shí)能取得較好的臨床療效,是一種快速、強(qiáng)效、安全的抗乙型肝炎病毒藥物。
[Abstract]:Objective to investigate the short-term clinical effect of entecavir dispersible tablets in the treatment of chronic viral hepatitis B with acute liver failure. Methods the clinical data of 98 patients with chronic viral hepatitis B and acute hepatic failure were analyzed retrospectively and divided into observation group and control group. Both groups were treated with routine medical comprehensive therapy. 56 cases were treated with entecavir dispersible tablets as the observation group, 42 cases were treated with entecavir tablets as the control group. The difference of hepatitis B virus DNA, liver function, prothrombin time and mortality after 12 weeks treatment were compared between the two groups. Results the level of hepatitis B virus DNA decreased rapidly in the two groups. At the 12th week of treatment, 40 patients in the observation group (71.43) and 31 patients in the control group (73.81) were treated with hepatitis B virus DNA500 IU/m L. There was no significant difference between the two groups at week 12 (20.068) (P 0.05). The levels of alanine aminotransferase, aspartate aminotransferase and total bilirubin in the two groups were significantly lower than those before treatment, and the serum albumin level was significantly increased and PT was shortened. There was no significant difference between the two groups (P 0.05). At 12 weeks, the mortality of the observation group was 32.14 / 56, and that of the control group was 30.95 / 42. There was no significant difference between the two groups (P 0.05). No adverse reactions occurred in both groups. Conclusion Entecavir dispersible tablet is a rapid, effective and safe antiviral drug in the treatment of chronic hepatitis B with acute liver failure.
【作者單位】： 川北醫(yī)學(xué)院附屬醫(yī)院感染科;
【分類(lèi)號(hào)】：R512.62;R575.3

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 曹慧;張e，

本文編號(hào)：1971633